Kymera Therapeutics Stock Climbs On Accelerated Timeline For Lead Atopic Dermatitis Program - Kymera Ther

Kymera Therapeutics shares surged after completing KT-621 Phase 2b enrollment early, accelerating data timing and Phase 3 plans.

Raccontata dabenzinga.com